Murphy Capital Management’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q2 | $4.09M | Buy |
78,029
+730
| +0.9% | +$37.2K | 0.57% | 48 |
|
|
2022
Q1 | $4M | Buy |
77,299
+83
| +0.1% | +$4.31K | 0.46% | 54 |
|
|
2021
Q4 | $4.56M | Buy |
77,216
+904
| +1% | +$44.8K | 0.49% | 52 |
|
|
2021
Q3 | $3.28M | Sell |
76,312
-5,175
| -6% | -$229K | 0.38% | 62 |
|
|
2021
Q2 | $3.19M | Buy |
81,487
+8,639
| +12% | +$336K | 0.36% | 65 |
|
|
2021
Q1 | $2.64M | Buy |
72,848
+5,795
| +9% | +$206K | 0.33% | 68 |
|
|
2020
Q4 | $2.47M | Sell |
67,053
-733
| -1% | -$26.9K | 0.33% | 68 |
|
|
2020
Q3 | $2.36M | Buy |
67,786
+5,266
| +8% | +$185K | 0.34% | 68 |
|
|
2020
Q2 | $1.94M | Buy |
62,520
+5,409
| +9% | +$184K | 0.31% | 77 |
|
|
2020
Q1 | $1.77M | Sell |
57,111
-3,441
| -6% | -$117K | 0.34% | 72 |
|
|
2019
Q4 | $2.25M | Sell |
60,552
-171
| -0.3% | -$6.09K | 0.32% | 76 |
|
|
2019
Q3 | $2.07M | Buy |
60,723
+1,675
| +3% | +$60.9K | 0.31% | 79 |
|
|
2019
Q2 | $2.43M | Buy |
59,048
+1,967
| +3% | +$78.1K | 0.36% | 70 |
|
|
2019
Q1 | $2.3M | Sell |
57,081
-3,779
| -6% | -$151K | 0.35% | 71 |
|
|
2018
Q4 | $2.52M | Sell |
60,860
-2,958
| -5% | -$123K | 0.42% | 62 |
|
|
2018
Q3 | $2.67M | Buy |
63,818
+1,111
| +2% | +$42.8K | 0.37% | 68 |
|
|
2018
Q2 | $2.16M | Sell |
62,707
-1,418
| -2% | -$48.5K | 0.31% | 83 |
|
|
2018
Q1 | $2.16M | Sell |
64,125
-1,914
| -3% | -$65.8K | 0.31% | 86 |
|
|
2017
Q4 | $2.27M | Sell |
66,039
-567
| -0.9% | -$19.3K | 0.31% | 87 |
|
|
2017
Q3 | $2.26M | Buy |
66,606
+1,297
| +2% | +$41.7K | 0.32% | 83 |
|
|
2017
Q2 | $2.08M | Buy |
65,309
+214
| +0.3% | +$6.75K | 0.31% | 84 |
|
|
2017
Q1 | $2.11M | Sell |
65,095
-2,177
| -3% | -$68.6K | 0.31% | 80 |
|
|
2016
Q4 | $2.07M | Sell |
67,272
-4,822
| -7% | -$147K | 0.33% | 80 |
|
|
2016
Q3 | $2.32M | Buy |
72,094
+987
| +1% | +$33K | 0.36% | 73 |
|
|
2016
Q2 | $2.38M | Buy |
71,107
+3,180
| +5% | +$101K | 0.37% | 73 |
|
|
2016
Q1 | $1.91M | Buy |
67,927
+3,672
| +6% | +$105K | 0.3% | 87 |
|
|
2015
Q4 | $1.97M | Buy |
64,255
+3,863
| +6% | +$122K | 0.3% | 82 |
|
|
2015
Q3 | $1.8M | Buy |
60,392
+5,826
| +11% | +$187K | 0.3% | 96 |
|
|
2015
Q2 | $1.74M | Buy |
54,566
+1,990
| +4% | +$64.9K | 0.26% | 101 |
|
|
2015
Q1 | $1.74M | Buy |
52,576
+4,223
| +9% | +$134K | 0.26% | 103 |
|
|
2014
Q4 | $1.43M | Sell |
48,353
-1,564
| -3% | -$44.8K | 0.22% | 117 |
|
|
2014
Q3 | $1.4M | Buy |
49,917
+1,988
| +4% | +$55.8K | 0.22% | 118 |
|
|
2014
Q2 | $1.35M | Buy |
47,929
+2,980
| +7% | +$84.9K | 0.21% | 120 |
|
|
2014
Q1 | $1.37M | Sell |
44,949
-2,135
| -5% | -$63.7K | 0.23% | 113 |
|
|
2013
Q4 | $1.37M | Buy |
47,084
+5,170
| +12% | +$150K | 0.24% | 105 |
|
|
2013
Q3 | $1.14M | Sell |
41,914
-1,671
| -4% | -$45.5K | 0.22% | 120 |
|
|
2013
Q2 | $1.16M | Buy |
+43,585
| New | +$1.2M | 0.24% | 110 |
|
Other funds holding PFE
Murphy Capital Management's PFE Position: Q2 2022 in Review
Murphy Capital Management increased its Pfizer (PFE) stake by 0.94% in Q2 2022, buying an estimated $37.2K and bringing the position to 78,029 shares worth $4.09M. The position accounts for 0.57% of the portfolio, ranked #48.
Murphy Capital Management first reported a position in PFE in Q2 2013 and has held it in 37 quarters since. The position peaked at $4.56M in Q4 2021. 3,157 funds tracked by Wall St. Rank hold PFE as of Q2 2022.
- Murphy Capital Management held 78,029 shares of Pfizer worth $4.09M as of Q2 2022.
- Murphy Capital Management bought 730 Pfizer shares in Q2 2022, an estimated $37.2K.
- Pfizer made up 0.57% of Murphy Capital Management's portfolio in Q2 2022, its #48 holding.
- Murphy Capital Management first reported a position in Pfizer in Q2 2013 and has held it in 37 quarters since.
- Murphy Capital Management's Pfizer position peaked at $4.56M in Q4 2021.
- 3,157 funds tracked by Wall St. Rank held Pfizer as of Q2 2022.
Based on Murphy Capital Management's 13F filing for Q2 2022, filed 13 Jul 2022.